Meta Information
ID:trazodone
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-05-25T18:50:05.062584+00:00
Model
claude-sonnet-4.6-wave15-stub-rebuild
Interactions
Target id:
/class/maois
Target name:
MAO Inhibitors (CONTRAINDICATED)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Coadministration of trazodone with MAOIs is contraindicated.
Actionable advice:
This combination should be avoided; if unavoidable, it should be managed under specialist supervision with intensive monitoring.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Concomitant use of monoamine oxidase inhibitors (MAOIs), or use within 14 days of stopping MAOIs ( 4 ).
Label source:
FDA label: Trazodone
Action type:
avoid
Target id:
/class/ssris-snris
Target name:
SSRIs / SNRIs (Serotonin Syndrome Risk)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Concomitant use with SSRIs/SNRIs increases serotonin syndrome risk.
Actionable advice:
This combination should be avoided; if unavoidable, it should be managed under specialist supervision with intensive monitoring.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
e reuptake inhibitors (SNRIs) and SSRIs, including trazodone hydrochloride tablets, can precipitate serotonin syndrome, a potentially life-threatening condition.
Label source:
FDA label: Trazodone
Action type:
avoid
Target id:
/class/cyp3a4-inhibitors
Target name:
Strong CYP3A4 Inhibitors
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) increase trazodone exposure.
Actionable advice:
This is best used with caution, and it is a good idea to monitor for clinical effect; dose adjustment or monitoring may be required.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
CYP3A4 Inducers: Increase in trazodone hydrochloride tablets dosage may be necessary ( 2.5 , 7 ).
Label source:
FDA label: Trazodone
Action type:
adjust_with_prescriber
Target id:
/class/cyp3a4-inducers
Target name:
CYP3A4 Inducers (Carbamazepine, Rifampin)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
CYP3A4 inducers (carbamazepine, rifampin, phenytoin) decrease trazodone exposure.
Actionable advice:
This is best used with caution, and it is a good idea to monitor for clinical effect; dose adjustment or monitoring may be required.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Examples: rifampin, carbamazepine, phenytoin, St.
Label source:
FDA label: Trazodone
Action type:
adjust_with_prescriber
Target id:
/class/cns-depressants
Target name:
CNS Depressants / Alcohol
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Additive sedation with alcohol and other CNS depressants.
Actionable advice:
This is best used with caution, and it is a good idea to monitor for clinical effect; dose adjustment or monitoring may be required.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
7 DRUG INTERACTIONS CNS Depressants: Trazodone hydrochloride tablets may enhance effects of alcohol, barbiturates, or other CNS depressants ( 7 ).
Label source:
FDA label: Trazodone
Action type:
adjust_with_prescriber
Target id:
/intervention/digoxin
Target name:
Digoxin
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Trazodone may increase digoxin serum levels; monitor.
Actionable advice:
This is best used with caution, and it is a good idea to monitor for clinical effect; dose adjustment or monitoring may be required.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Digoxin or Phenytoin: Monitor for increased digoxin or phenytoin serum levels ( 7 ).
Label source:
FDA label: Trazodone
Action type:
adjust_with_prescriber
Target id:
/intervention/warfarin
Target name:
Warfarin
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Variable effects on prothrombin time reported with warfarin; monitor INR.
Actionable advice:
This is best used with caution, and it is a good idea to monitor for clinical effect; dose adjustment or monitoring may be required.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
For patients taking warfarin, carefully monitor coagulation indices when initiating, titrating, or discontinuing trazodone hydrochloride.
Label source:
FDA label: Trazodone
Action type:
adjust_with_prescriber
Target id:
/condition/qt-prolongation-risk
Target name:
QT Prolongation
Severity:
major
Interaction type:
contraindication
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Trazodone has been associated with QT-interval prolongation and torsade de pointes.
Actionable advice:
This combination should be avoided; if unavoidable, it should be managed under specialist supervision with intensive monitoring.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
The use of trazodone hydrochloride should be avoided in patients with known QT prolongation
Label source:
FDA label: Trazodone
Action type:
avoid
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Limited human data; use during pregnancy only if benefits justify risks.
Actionable advice:
Use should be avoided during pregnancy unless the benefit clearly outweighs the risk, and it is worth discussing with a prescriber.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Healthcare providers are encouraged to register patients by calling the National Pregnan
Label source:
FDA label: Trazodone
Action type:
avoid
Target id:
/condition/lactation
Target name:
Lactation
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Trazodone metabolites are excreted in human milk; use with caution.
Actionable advice:
It is important to talk to a prescriber about risk/benefit before nursing; alternatives or temporary cessation may be warranted.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
8.2 Lactation Risk Summary Data from published literature report the transfer of trazodone into human milk.
Label source:
FDA label: Trazodone
Action type:
informational_none
Target id:
/condition/elderly
Target name:
Elderly
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Elderly patients are more sensitive to orthostatic and sedative effects; start at lower dose.
Actionable advice:
Lower starting doses with slow titration are best, and it is a good idea to monitor for adverse effects.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
inical literature and experience with trazodone has not identified differences in responses between elderly and younger patients.
Label source:
FDA label: Trazodone
Action type:
adjust_with_prescriber
Target id:
/adverse/priapism
Target name:
Priapism
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Priapism is a known risk; men should be advised to seek emergency care for prolonged erections >4 hours.
Actionable advice:
This combination should be avoided; if unavoidable, it should be managed under specialist supervision with intensive monitoring.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Priapism: Cases of painful and prolonged penile erections and priapism have been reported.
Label source:
FDA label: Trazodone
Action type:
avoid
Target id:
/adverse/orthostatic-hypotension
Target name:
Orthostatic Hypotension
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Orthostatic hypotension and syncope can occur, especially at initiation.
Actionable advice:
This is best used with caution, and it is a good idea to monitor for clinical effect; dose adjustment or monitoring may be required.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
5.4 Orthostatic Hypotension and Syncope Hypotension, including orthostatic hypotension and syncope has been reported in patients receiving trazodone hydrochloride.
Label source:
FDA label: Trazodone
Action type:
adjust_with_prescriber
Target id:
/adverse/suicidality
Target name:
Suicidality (BOXED, Pediatric/Young Adult)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Antidepressants carry boxed warning for suicidality in children, adolescents, and young adults.
Actionable advice:
This combination should be avoided; if unavoidable, it should be managed under specialist supervision with intensive monitoring.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning.
Label source:
FDA label: Trazodone
Action type:
avoid